304 related articles for article (PubMed ID: 21152689)
41. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
42. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
[TBL] [Abstract][Full Text] [Related]
43. Positron Emission Tomography (PET) and breast cancer in clinical practice.
Lavayssière R; Cabée AE; Filmont JE
Eur J Radiol; 2009 Jan; 69(1):50-8. PubMed ID: 18814983
[TBL] [Abstract][Full Text] [Related]
44. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
45. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
[TBL] [Abstract][Full Text] [Related]
46. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
47. PET beyond ¹⁸F-FDG: second generation PET tracers in clinical oncology.
Brouwers AH; Glaudemans AW; De Vries EF
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):1-3. PubMed ID: 25854554
[No Abstract] [Full Text] [Related]
48. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
49. How to use PET/CT in the evaluation of response to radiotherapy.
Decazes P; Thureau S; Dubray B; Vera P
Q J Nucl Med Mol Imaging; 2018 Jun; 62(2):152-164. PubMed ID: 29186937
[TBL] [Abstract][Full Text] [Related]
50. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
Basu S; Alavi A
PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
[TBL] [Abstract][Full Text] [Related]
51. Standardization and quantification in PET/CT imaging: tracers beyond FDG.
Antunovic L; Rodari M; Rossi P; Chiti A
PET Clin; 2014 Jul; 9(3):259-66. PubMed ID: 25030389
[TBL] [Abstract][Full Text] [Related]
52. [The use of 18F-fluorothymidine and 18F-fluorocholine in imaging with positron emission tomography].
Skoura E; Datseris IE
Hell J Nucl Med; 2010; 13(1):88-90. PubMed ID: 20411184
[TBL] [Abstract][Full Text] [Related]
53. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
Monazzam A; Josephsson R; Blomqvist C; Carlsson J; Långström B; Bergström M
Breast Cancer Res; 2007; 9(4):R45. PubMed ID: 17659092
[TBL] [Abstract][Full Text] [Related]
54. 11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?
Nanni C; Castellucci P; Farsad M; Rubello D; Fanti S
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1704-5. PubMed ID: 17619877
[No Abstract] [Full Text] [Related]
55. Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model.
Emonds KM; Swinnen JV; Lerut E; Koole M; Mortelmans L; Mottaghy FM
EJNMMI Res; 2013 Apr; 3(1):31. PubMed ID: 23618081
[TBL] [Abstract][Full Text] [Related]
56. Proliferation markers for the differential diagnosis of tumor and inflammation.
van Waarde A; Elsinga PH
Curr Pharm Des; 2008; 14(31):3326-339. PubMed ID: 19075707
[TBL] [Abstract][Full Text] [Related]
57. PET imaging of proliferation with pyrimidines.
Tehrani OS; Shields AF
J Nucl Med; 2013 Jun; 54(6):903-12. PubMed ID: 23674576
[TBL] [Abstract][Full Text] [Related]
58. New PET imaging agents in the management of solid cancers.
Garcia C; Gebhart G; Flamen P
Curr Opin Oncol; 2012 Nov; 24(6):748-55. PubMed ID: 22913970
[TBL] [Abstract][Full Text] [Related]
59. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography.
Wijsman R; Kaanders JH; Oyen WJ; Bussink J
Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):244-56. PubMed ID: 24045621
[TBL] [Abstract][Full Text] [Related]
60. PET/CT imaging in different types of lung cancer: an overview.
Ambrosini V; Nicolini S; Caroli P; Nanni C; Massaro A; Marzola MC; Rubello D; Fanti S
Eur J Radiol; 2012 May; 81(5):988-1001. PubMed ID: 21458181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
